Gerresheimer joins the Science Based Targets initiative

 - Gerresheimer AG
  • SBTi provides science-based framework for companies’ climate action targets
  • Gerresheimer to have CO2 reduction targets validated by SBTi
  • Plans in place to cut Scope 1 and 2 emissions by 50% by 2030

Duesseldorf, August 23, 2023. Gerresheimer, innovative system and solution provider and global partner for the pharma and biotech industry, has joined the Science Based Targets initiative (SBTi). The organization supports companies in using sound science to set and work toward targets for reducing greenhouse gas emissions. The SBTi will verify whether Gerresheimer’s own CO2 reduction targets are in line with the Paris Agreement before transparently documenting the company’s progress on its platform. By 2030, Gerresheimer aims to reduce its Scope 1 and Scope 2 emissions by 50% compared to the base year 2019. In addition, the company has committed itself to setting a specific reduction target for Scope 3 emissions within the next 24 months. By joining the SBTi, Gerresheimer is underscoring its ambitious sustainability targets as part of its formula g corporate strategy.

“As a global partner to the pharma and biotech industry, we want to help improve the quality of life of millions of patients worldwide through our products and solutions,” says Dietmar Siemssen, CEO of Gerresheimer AG. “Sustainability – especially responsibility for the climate impact of our operating business – is an inseparable part of that for us.” 

Reduction targets in line with the Paris Agreement

As part of its formula g corporate strategy, Gerresheimer aims to reduce its Scope 1 and Scope 2 emissions by 50% by 2030. Scope 1 emissions include all emissions that Gerresheimer causes directly in the course of its business activities. Indirect emissions generated to produce and source energy are included in Scope 2 emissions. Gerresheimer plans to use state-of-the-art production technology to reduce energy demand while meeting 100% of its electricity needs from renewable sources by 2030.

The SBTi will validate whether the Scope 1 and 2 reduction targets are in line with the Paris Agreement, which aims to limit global warming to 1.5°C by 2050.

Over the next two years, Gerresheimer will also formulate targets for reducing Scope 3 emissions in accordance with the SBTi’s best practice guidelines. Scope 3 includes indirect emissions that occur in the upstream and downstream value chain, such as in connection with the procurement of raw materials from suppliers, logistics processes, or subsequent disposal.

SBTi – framework for science-based climate change mitigation

The Science Based Targets initiative was founded in 2015 by CDP (formerly the Carbon Disclosure Project), the United Nations Global Compact (UNGC), the World Resources Institute (WRI), and the World Wide Fund for Nature (WWF). It provides companies with a clearly defined framework for reducing emissions in accordance with the latest scientific findings and in line with the goals of the Paris Agreement, allowing them to help limit global warming. More than 5,700 companies around the world have already joined the initiative.  

Transparent sustainability reporting

Joining the SBTi underpins Gerresheimer’s goal of providing transparent, sound, and comparable information on its sustainability activities, targets, measures, and outcomes in accordance with best practice standards.

In addition to publishing a sustainability report every year, Gerresheimer also discloses relevant data as part of the ratings issued by CDP, EcoVadis, and other organizations. MSCI, Sustainalytics, and ISS also evaluate Gerresheimer’s sustainability performance. An overview of Gerresheimer’s external sustainability ratings can be found here.


About Gerresheimer

Gerresheimer is the innovative system and solution provider and global partner for the pharma and biotech industry. The company offers a comprehensive portfolio of pharmaceutical containment solutions, drug delivery systems and medical devices as well as solutions for the health and cosmetics industry. The product range includes digital solutions for therapy support, medication pumps, syringes, pens, auto-injectors and inhalers as well as vials, ampoules, tablet containers, dropper bottles, other bottles and more. Gerresheimer ensures the safe delivery and administration of drugs to the patient. With 36 production sites in 16 countries in Europe, America and Asia, Gerresheimer has a global presence and produces locally for the regional markets. With over 11,000 employees, the company generated revenues of around €1.82bn in 2022. Gerresheimer AG is listed in the MDAX on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6). 


Contact Gerresheimer AG

Jutta Lorberg
Head of Corporate Communication
P +49 211 6181 264

Marion Stolzenwald
Senior Manager Corporate Communication
P +49 172 24 24 185


Contact us!

Communication & Marketing

Phone: +49 211 61 81 246